<DOC>
	<DOCNO>NCT01249690</DOCNO>
	<brief_summary>The primary purpose study evaluate efficacy PAD-regimen TAD-regimen newly diagnose multiple myeloma ( MM ) .</brief_summary>
	<brief_title>Efficacy Study PAD TAD Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description>Multiple myeloma ( MM ) malignant tumor abnormal proliferation monoclonal plasma cell bone marrow . Bone damage one characteristic clinical manifestation . Myeloma plasma cell bone marrow microenvironment target thalidomide bortezomib . The regimen base first-line treatment MM greatly improve efficacy prolong survival MM patient . But whether regimen prevent treat bone complication MM patient improve quality life clear . By evaluate efficacy PAD-regimen ( Bortezomib , Pirarubicin Dexamethasone ) TAD-regimen ( Thalidomide , Pirarubicin Dexamethasone ) MM effect bone lesion , study provide evidence evidence-based medicine MM treatment .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pirarubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Subjects symptomatic measurable newly diagnose Multiple Myeloma . Age &gt; 18 year , KPS ≥ 60 , life expectancy least 3 month . Subjects must meet follow criterion within 14 day start therapy : PLT≥50×109/L , Hb≥70 g/L , ANC≥0.75×109/L Subjects ( legally acceptable representative ) must sign informed consent document . Severe cardiovascular disease ; HIV infection , positive HBsAg , active hepatitis C ; HBVDNA &gt; 104 ; hepatic functional parameter &gt; 2.5 time upper limit institutional laboratory normal . Grade 2 severe peripheral neuropathy neuropathic pain ; Grade 2 severe impaired hepatic kidney function . Patient radiotherapy major surgery within 30 day enrollment . Patient hypersensitivity boron , mannitol thalidomide . Pregnant breastfeed woman , subject unwilling use method contraception study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Bortezomib , Thalidomide , bone metabolite</keyword>
</DOC>